



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

125B
CASWELL FILE

8-18-92

009678

AUG 18 1992

MEMORANDUM

OFFICE OF
PESTICIDES AND TOXIC
SUBSTANCES

SUBJECT: Requested review of "Supplement to a 28-day Dermal Toxicity Study in Rabbits - Terbutylazine - MRID No. 405148-02."

Tox.Chem No.: 125B
MRID No.: 420598-04
HED Project No.: 2-1012
Submission No.: S409513
DP Barcode No.: D173032

To: Bruce Sidwell, PMT 53
Accelerated Reregistration Branch
Special Review and Reregistration Division (H7508W)

From: John C. Redden, M.S. *CJR 7/27/92*
Section 3
Toxicology Branch 1
Health Effects Division (H7509C)

Thru: Karen Hamernik, Ph.D. *K. Hamernik 8/11/92*
Acting, Section Head Section 3
Toxicology Branch 1
Health Effects Division (H7509C)

ACTION:

Requested review of "Supplement to a 28-day Dermal Toxicity Study in Rabbits - Terbutylazine - MRID No. 405148-02."

CONCLUSIONS:

The purity of the test compound, Terbutylazine Technical is 97.1 %. The stability of the compound was tested, and it was reported that the compound did not decompose significantly over time. Therefore, the 28-Day Dermal Toxicity Study in Rabbits MRID No. 405148-02, Guidelines § 82-2, is upgraded to Core Guideline.

BACKGROUND:

This study was originally reviewed in May 1988, HED Document No. 006728. Two studies were reviewed in this document a 28-day oral study, MRID No. 405148-01, and a 28-dermal toxicity study, MRID No. 405148-02.

009678

At that time MRID No. 405148-02 was graded as Guideline. As a result of Phase IV review, the study was reclassified as supplemental because it was determined that the purity and stability of the compound, Terbutylazine Batch Number FL-860558, had not been provided.

The supplement (Report MIN862131; 8/22/91) supplied by the sponsor, MRID No. 420598-04, provides the purity and an analysis of the stability of Terbutylazine Batch No. FL-860558. The purity of Terbutylazine Technical is 97.1 %. The stability of the compound was analyzed by a GC capillary method. Results of the analysis of stability found, "no significant decomposition of Terbutylazine Technical."

The Dermal-28 day Study MRID No. 405148-02 has been upgraded to Core Guideline.